Partition of bispyridinium oximes (trimedoxime and K074) administered in therapeutic doses into different parts of the rat brain
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
21146949
DOI
10.1016/j.jpba.2010.11.024
PII: S0731-7085(10)00667-9
Knihovny.cz E-resources
- MeSH
- Butanes administration & dosage blood isolation & purification pharmacokinetics pharmacology MeSH
- Injections, Intramuscular MeSH
- Calibration MeSH
- Rats MeSH
- Limit of Detection MeSH
- Molecular Structure MeSH
- Brain metabolism MeSH
- Oximes administration & dosage blood isolation & purification pharmacokinetics pharmacology MeSH
- Rats, Wistar MeSH
- Pyridinium Compounds administration & dosage blood isolation & purification pharmacokinetics pharmacology MeSH
- Cholinesterase Reactivators administration & dosage blood isolation & purification pharmacokinetics pharmacology MeSH
- Reference Standards MeSH
- Regression Analysis MeSH
- Reproducibility of Results MeSH
- Tissue Distribution MeSH
- Trimedoxime administration & dosage blood isolation & purification pharmacokinetics pharmacology MeSH
- Chromatography, High Pressure Liquid instrumentation MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 1,4-bis(4-hydroxyiminomethylpyridinium)butane dibromide MeSH Browser
- Butanes MeSH
- Oximes MeSH
- Pyridinium Compounds MeSH
- Cholinesterase Reactivators MeSH
- Trimedoxime MeSH
The penetration of acetylcholinesterase reactivators (oximes) into the central nervous system is typically restricted by the blood-brain barrier. Although oximes are highly hydrophilic compounds, some contradictory results confirming permeation into the brain exist. The aim of this study is to verify the penetration of oximes through the blood-brain barrier and to detect their levels achieved in different brain regions 60 min after the administration. It was confirmed that oximes are able to penetrate into the brain after injection of therapeutic doses corresponding with 5% of LD(50). The level in whole brain was 0.58% for trimedoxime and 0.85% for the experimental drug oxime K074 as the percentage of their plasma concentration. The highest concentration was found in frontal cortex (trimedoxime 2.27%; oxime K074 0.95%) and lowest in basal ganglia (trimedoxime 0.86%; oxime K074 0.42%). Entry of oximes into the brain is minimal, but some low reactivation effect should be expected. The reactivation potency of oximes might be higher or lower, depending on the real oxime concentration in a given area.
References provided by Crossref.org
Brominated oxime nucleophiles are efficiently reactivating cholinesterases inhibited by nerve agents
Strategies for enhanced bioavailability of oxime reactivators in the central nervous system
Time-dependent changes of oxime K027 concentrations in different parts of rat central nervous system